Scientific due diligence asks whether the evidence supports the claim. Ontomics provides independent scientific due diligence for investors, founders, research organizations, universities, biotechnology teams, life sciences companies, and executive leaders evaluating scientific claims before funding, licensing, acquisition, commercialization, or continued development.
Our objective is to evaluate the mechanism, evidence, assumptions, limitations, reproducibility, technical interpretation, and pathway behind the science.
Let's See If We Can HelpIndependent scientific review evaluates whether observations, experiments, models, mechanisms, and interpretations support the conclusions being used to guide technical or commercial decisions. Ontomics looks for what the evidence can support, what remains uncertain, and which assumptions are doing the most work.
Research validation requires more than promising results. Ontomics reviews whether the scientific pathway is reproducible, technically coherent, mechanistically plausible, and strong enough to justify the next stage of investment, development, or commercialization.
Scientific claims can become risky when strong language outruns the evidence. Ontomics evaluates claims, models, experimental design, technical documentation, and competing explanations to determine whether the stated conclusions remain defensible.
Scientific discoveries must survive translation into product, platform, licensing, regulatory, manufacturing, and market pathways. Ontomics evaluates whether the underlying science can support the commercial decisions being made around it.
Scientific due diligence is valuable before venture funding, licensing, acquisition, university technology transfer, clinical translation, regulatory planning, grant expansion, commercialization, or major research investment.
Ontomics evaluates whether the evidence, mechanism, model, experimental design, reproducibility, and technical interpretation support the decision being made.
Incomplete evidence does not always mean a project should stop. It may mean the next pathway needs to be engineered around the specific assumptions, tests, and uncertainties that matter most.
Yes. Investors often need an independent review of the scientific mechanism, technical evidence, research maturity, translation risk, commercialization pathway, and unanswered questions before capital is committed.
That is still useful. A clear review can identify which assumptions, evidence gaps, mechanisms, or validation steps should be addressed before more money, time, or reputation is committed.
Independent Technical Review • Technical Audit • Mechanism Investigation • Technology Validation • Research Infrastructure • Pathway Engineering
If your organization needs to evaluate scientific claims, research evidence, biotechnology platforms, life sciences programs, technical models, or commercialization pathways, Ontomics provides independent scientific due diligence focused on what the evidence can actually support.
The point is not to make the science sound stronger. The point is to understand whether it is.
Start the Conversation